Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Ment Health Policy Econ. 2004 Jun;7(2):77-85.

Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.

Author information

  • 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, 1620 Tremont Street, Suite 3030 Boston, MA 02120, USA. pwang@rics.bwh.harvard.edu

Abstract

BACKGROUND:

Clozapine is currently restricted to patients who have failed at least two trials of other antipsychotic medications because of concerns that its use as a first-line agent would lead to greater mortality, mainly through agranulocytosis.

AIMS OF THE STUDY:

We sought to determine the cost-effectiveness of allowing clozapine to be a first-line treatment versus the current policy of restricting clozapine to third-line status.

METHODS:

We performed a cost-effectiveness analysis using published data from randomized controlled trials and epidemiologic studies. The target population was patients with schizophrenia in an acute psychotic episode, with a lifetime time horizon and societal perspective. Outcome measures included life expectancy, quality-adjusted life expectancy, costs, and cost-effectiveness ratios.

RESULTS:

Using clozapine as a first agent would lead to modest gains in life-expectancy as well as quality-adjusted life expectancy, relative to restricting its use to patients who failed 2 conventional antipsychotics. The cost-effectiveness ratio of using clozapine first vs. using clozapine third would be $24,100 per quality-adjusted life year (QALY). In 1-way and probabilistic sensitivity analyses, these findings were robust to a variety of assumptions.

DISCUSSION:

Allowing clozapine to be a first-line agent may lead to small gains in life expectancy at moderate but acceptable costs.

IMPLICATIONS:

While these results do not shed light on whether clozapine should be the preferred first-line strategy, they do suggest that clozapine should be added to the armamentarium of possible treatments for treatment-sensitive as well as treatment-resistant schizophrenia.

PMID:
15208468
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for International Center of Mental Health Policy and Economics
    Loading ...
    Write to the Help Desk